Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure.
Schneider HJ, Husser O, Rihm M, Fredersdorf S, Birner C, Dhein S, Muders F, Jeron A, Goegelein H, Riegger GA, Luchner A.
Schneider HJ, et al. Among authors: dhein s.
Naunyn Schmiedebergs Arch Pharmacol. 2009 Mar;379(3):225-32. doi: 10.1007/s00210-008-0361-0. Epub 2008 Oct 30.
Naunyn Schmiedebergs Arch Pharmacol. 2009.
PMID: 18972103